CoChat

Effects of GLP-1 receptor agonists on neurological complications of diabetes

Open access
García-Casares, Natalia, González-González, Guillermo, de la Cruz-Cosme, Carlos, Garzón-Maldonado, Francisco J, de Rojas-Leal, Carmen, Ariza, María J, Narváez, Manuel, Barbancho, Miguel Ángel, García-Arnés, Juan Antonio, Tinahones, Francisco J. · 2023 · Reviews in Endocrine and Metabolic Disorders
Cited by 45

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy. We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy. Semaglutide subcutaneous and dulaglutide reduced stroke cases. Liraglutide, albiglutide, oral semaglutide and efpeglenatide, were not shown to reduce the number of strokes but did reduce major cardiovascular events. Exenatide, dulaglutide and liraglutide improved general cognition but no significant effect on diabetic peripheral neuropathy has been reported with GLP-1 RAs. GLP-1 RAs are promising drugs that seem to be useful in the reduction of some neurological complications of diabetes. However, more studies are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11154-023-09807-3

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 45

Metadata

Authors
García-Casares, N., González-González, G., de la Cruz-Cosme, C., Garzón-Maldonado, F. J., de Rojas-Leal, C., Ariza, M. J., Narváez, M., Barbancho, M. Á., García-Arnés, J. A., & Tinahones, F. J.
Venue
Reviews in Endocrine and Metabolic Disorders
Published
2023-05-26
Volume
24
Issue
4
Pages
655-672
ISSN
  • 1389-9155 (ISSN-L)
  • 1573-2606
OpenAlex
W4378349085
Cited by
45
References
27
FWCI
7.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of GLP-1 receptor agonists on neurological complications of diabetes. https://app.cochat.ai/papers/10.1007/s11154-023-09807-3
The paper
García-Casares, N., González-González, G., de la Cruz-Cosme, C., Garzón-Maldonado, F. J., de Rojas-Leal, C., Ariza, M. J., Narváez, M., Barbancho, M. Á., García-Arnés, J. A., & Tinahones, F. J. (2023). Effects of GLP-1 receptor agonists on neurological complications of diabetes. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-023-09807-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.